Related Experiment Video

Updated: Aug 10, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Value of short-course antimicrobial therapy in community-acquired pneumonia

Francesco Blasi1, Paolo Tarsia

  • 1Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena Milano, Italy. francesco.blasi@unimi.it

International Journal of Antimicrobial Agents
|March 18, 2006
PubMed

Insights

Short-course therapy for community-acquired pneumonia (CAP) improves patient compliance. A single 2.0 g dose of azithromycin microspheres offers an effective alternative to traditional 7-day antibiotic regimens for CAP.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Pulmonology

Background:

  • Community-acquired pneumonia (CAP) is a significant global health concern, contributing to substantial morbidity and mortality.
  • Non-compliance with CAP therapy can lead to treatment failure, disease progression, and increased healthcare costs.
  • Factors influencing adherence include dosing schedules, treatment duration, side effects, and palatability, particularly in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy and compliance of short-course antimicrobial therapy for community-acquired pneumonia (CAP).
  • To investigate azithromycin's potential for improved treatment compliance through single-dose administration.
  • To compare a single 2.0 g dose of azithromycin microspheres with standard 7-day regimens.

Main Methods:

  • Two Phase III clinical trials were conducted to assess community-acquired pneumonia (CAP) treatment outcomes.
  • Azithromycin microspheres were administered as a single 2.0 g dose.
  • Treatment efficacy was compared against 7-day courses of clarithromycin XL and levofloxacin.

Main Results:

  • A single 2.0 g dose of azithromycin microspheres demonstrated suitability as an alternative to 7-day clarithromycin XL therapy.
  • This single-dose azithromycin regimen was also found to be a viable alternative to 7-day levofloxacin therapy.
  • Short-course therapy, exemplified by the single-dose azithromycin, shows promise in improving patient compliance.

Conclusions:

  • Single-dose azithromycin microspheres (2.0 g) present a viable and potentially compliance-enhancing option for community-acquired pneumonia (CAP) treatment.
  • Short-course antimicrobial strategies, particularly with azithromycin, may be as effective or superior to traditional longer durations.
  • Optimizing CAP treatment regimens through improved compliance can mitigate negative patient outcomes and reduce healthcare resource utilization.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...